Outcomes18

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 18 of 18

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Reduction in Primary Joint Contracture to 5° or Less	Within 30 days after last injection	Subjects who were randomized and received at least 1 injection	Percentage of Joints	NUMBER
SECONDARY	Clinical Improvement in Primary Joint After the Last Injection	Baseline, Within 30 days after last injection	Subjects who were randomized and received at least 1 injection	Percentage of Joints	NUMBER
SECONDARY	Percent Reduction From Baseline Contracture of Primary Joint After the Last Injection	Baseline, Day 30 after last injection	Subjects who were randomized and received at least 1 injection	Percentage of change	MEAN
SECONDARY	Change From Baseline Range of Motion in Primary Joint After the Last Injection	Baseline, Day 30 after last injection	Subjects who were randomized and received at least 1 injection	Degrees	MEAN
SECONDARY	Time to Reach Clinical Success in Primary Joint	Within 30 days after last injection	Subjects who were randomized and received at least 1 injection	Percentage of Joints	NUMBER
SECONDARY	Clinical Success in Primary Joint After the First Injection	Within 30 days after first injection	Subjects who were randomized and received at least 1 injection	Percentage of Joints	NUMBER
SECONDARY	Clinical Improvement in Primary Joint After the First Injection	Baseline, Within 30 days after first injection	Subjects who were randomized and received at least 1 injection	Percentage of Joints	NUMBER
SECONDARY	Percent Reduction From Baseline Contracture of Primary Joint After the First Injection	Baseline, Day 30 after first injection	Subjects who were randomized and received at least 1 injection	Percentage of change	MEAN
SECONDARY	Change From Baseline Range of Motion in Primary Joint After the First Injection	Baseline, Day 30 after first injection	Subjects who were randomized and received at least 1 injection	Degrees	MEAN
SECONDARY	Reduction in Non-primary Joint Contracture to 5° or Less After the Last Injection	Within 30 days after last injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Percentage of Joints	NUMBER
SECONDARY	Clinical Improvement in Non-Primary Joint After the Last Injection	Baseline, Within 30 days after last injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Percentage of Joints	NUMBER
SECONDARY	Percent Reduction From Baseline Contracture of Non-Primary Joint After the Last Injection	Baseline, Day 30 after last injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Percentage of change	MEAN
SECONDARY	Change From Baseline Range of Motion in Non-Primary Joint After the Last Injection	Baseline, Day 30 after last injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Degrees	MEAN
SECONDARY	Time to Reach Clinical Success in Non-Primary Joint	Within 30 days after last injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Percentage of Joints	NUMBER
SECONDARY	Clinical Success in Non-Primary Joint After the First Injection	Within 30 days after first injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Percentage of Joints	NUMBER
SECONDARY	Clinical Improvement in Non-Primary Joint After the First Injection	Baseline, Within 30 days after first injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Percentage of Joints	NUMBER
SECONDARY	Percent Reduction From Baseline Contracture of Non-Primary Joint After the First Injection	Baseline, Day 30 after first injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Percentage of change	MEAN
SECONDARY	Change From Baseline Range of Motion in Non-Primary Joint After the First Injection	Baseline, Day 30 after first injection	Includes evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture \>5° and at least 1 post-injection contracture measurement in subjects who received at least 1 non-primary joint injection in either study period	Degrees	MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00533273/outcomes

API reference For AI assistants